Physician profile
Ritu M Sachdev
NPI 1851568224
$2,389.53
in general payments reported to CMS, 2019-2025
22 companies · $474 in 2025
The $474 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $156 · 2021: $134 · 2022: $137 · 2023: $540 · 2024: $507 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $453.73 | 2019-2024 | Skyrizi, Rinvoq, Ubrelvy |
| Janssen Biotech, INC. | $271.89 | 2023-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $262.28 | 2019-2022 | |
| Madrigal Pharmaceuticals | $198.43 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $191.52 | 2019-2025 | Xifaxan |
| Pfizer INC. | $167.41 | 2019-2025 | |
| Celgene Corporation | $119.27 | 2021-2024 | Zeposia |
| Novo Nordisk INC | $118.47 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $103.95 | 2021-2025 | Proclaim, Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $67.84 | 2024 | Gemtesa |
| Braintree Laboratories, INC. | $57.22 | 2020-2023 | Sutab, Suflave |
| Ardelyx, INC. | $56.08 | 2024 | Ibsrela |
| Gilead Sciences, INC. | $55.48 | 2021-2023 | |
| Exact Sciences Corporation | $46.81 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $45.87 | 2024-2025 | Voquezna |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $42.72 | 2019 | |
| Allergan, INC. | $41.45 | 2019 | |
| Boston Scientific Corporation | $25.73 | 2024 | Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $18.23 | 2024 | Intellis Adaptivestim |
| Qol Medical, LLC | $17.42 | 2021 | |
| Sanofi Pasteur INC. | $15.42 | 2019 | |
| Nevro Corp. | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritu Sachdev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.